We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-1.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$67.6M
AUM Growth
-$6.2M
Cap. Flow
-$3.41M
Cap. Flow %
-5.05%
Top 10 Hldgs %
57.93%
Holding
76
New
1
Increased
16
Reduced
1
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$259K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$255K
3
EXAS
Exact Sciences
EXAS
+$246K
4
NKTR icon
Nektar Therapeutics
NKTR
+$73.7K
5
LGND icon
Ligand Pharmaceuticals
LGND
+$43.2K

Top Sells

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$506K
2
CLLS
Cellectis
CLLS
+$409K
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$408K
4
RUBY
Rubius Therapeutics, Inc
RUBY
+$391K
5
WVE icon
Wave Life Sciences
WVE
+$377K

Sector Composition

Rank Sector Weight
1 Healthcare 58.79%
2 Miscellaneous 41.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBB icon
1
iShares Biotechnology ETF
IBB
$10.8B
$13.6M 20.18%
125,000
– –
IBB icon
2
CALL
iShares Biotechnology ETF
IBB
$10.8B
$9.27M 13.72%
85,000
– –
LABU icon
3
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
$4.94M 7.31%
4,922
+21
+0.4% +$20.3K
MTD icon
4
Mettler-Toledo International
MTD
$28.2B
$2.72M 4.02%
3,235
– –
ILMN icon
5
Illumina
ILMN
$34.4B
$1.73M 2.56%
4,831
+25
+0.5% +$7.89K
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$139B
$1.5M 2.22%
8,193
+119
+1% +$20.8K
BMY icon
7
Bristol-Myers Squibb
BMY
$137B
$1.5M 2.21%
33,000
– –
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$1.3M 1.92%
9,927
– –
IONS icon
9
Ionis Pharmaceuticals
IONS
$10.4B
$1.29M 1.91%
20,124
– –
PRQR icon
10
ProQR Therapeutics
PRQR
$327M
$1.26M 1.86%
138,461
– –
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$1.24M 1.83%
17,901
+69
+0.4% +$4.83K
QGEN icon
12
Qiagen
QGEN
$9.03B
$1.17M 1.73%
27,215
– –
QURE icon
13
uniQure
QURE
$3.44B
$1.11M 1.64%
14,215
– –
EXAS
14
DELISTED
Exact Sciences
EXAS
$1.01M 1.49%
8,534
+2,441
+40% +$246K
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$993K 1.47%
9,699
– –
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$31.7B
$969K 1.43%
13,351
– –
INCY icon
17
Incyte
INCY
$25.9B
$902K 1.33%
10,613
– –
IMMU
18
DELISTED
Immunomedics Inc
IMMU
$868K 1.28%
62,575
– –
SRPT icon
19
Sarepta Therapeutics
SRPT
$2.28B
$813K 1.2%
5,353
+2,101
+65% +$255K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$12.6B
$805K 1.19%
9,400
+301
+3% +$25.7K
BLUE
21
DELISTED
bluebird bio
BLUE
$743K 1.1%
451
– –
ASND icon
22
Ascendis Pharma A/S
ASND
$16.4B
$713K 1.05%
6,190
– –
REGN icon
23
Regeneron Pharmaceuticals
REGN
$83.2B
$695K 1.03%
2,221
+20
+0.9% +$6.66K
INSM icon
24
Insmed
INSM
$26.5B
$690K 1.02%
26,936
– –
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$656K 0.97%
17,339
– –
1
2 3 4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opus Point Partners Management held 76 positions worth $67.6M, down 8.4% from $73.8M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opus Point Partners Management withdrew a net $3.41M in Q2 2019, closing 13 positions and reducing 1 holding. Its most notable exit was Regenxbio, an estimated $506K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Biogen worth $263K.

  • Opus Point Partners Management's largest Q2 2019 buy was Biogen: 1,123 shares worth $263K.
  • Opus Point Partners Management added most to Sarepta Therapeutics in Q2 2019, an estimated $255K increase.
  • Opus Point Partners Management's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $274K.
  • Opus Point Partners Management fully exited Regenxbio in Q2 2019, selling an estimated $506K.
  • Opus Point Partners Management's ten largest holdings make up 58% of its $67.6M portfolio in Q2 2019.
  • Opus Point Partners Management opened 1 new position and closed 13 in Q2 2019.
  • Opus Point Partners Management's portfolio value fell 8.4% quarter-over-quarter to $67.6M.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.